UBS has initiated coverage on Procept Biorobotics Corp (PRCT) with a Buy rating as of December 11, 2025. This marks the firm's first assessment of the company, reflecting its evaluation of Procept's investment potential amid evolving industry dynamics.
Headquartered in San Jose, California, Procept BioRobotics is a commercial-stage surgical robotics company focused on developing innovative solutions in urology. The company manufactures the AQUABEAM Robotic System, which utilizes advanced imaging and robotics to perform minimally invasive surgeries, specifically targeting benign prostatic hyperplasia (BPH). Currently, Procept employs 756 full-time staff and has a market capitalization of $1.7 billion.
As of November 25, 2025, Procept's earnings per share (EPS) stands at -1.54. The company is scheduled to report its next earnings on August 4, 2026, with an estimated EPS of -0.29 and revenue expectations of $104.8 million.
Analyst ratings often provide insights based on extensive research and financial modeling, yet they are grounded in assumptions that may not always hold true. Investors should consider a range of factors, including company fundamentals and market trends, when making decisions. Analyst opinions can evolve as new information arises, highlighting the importance of ongoing evaluation.
This update provides insight into Procept's standing in the market, with UBS's Buy rating contributing to the overall analyst consensus of 19 analysts, which includes 7 Strong Buy and 9 Buy ratings as of December 1, 2025.